Targeting the bone microenvironment in multiple myeloma
1Department of Medicine/Hematology-Oncology, Veterans Affairs Pittsburgh Healthcare System, University of Pittsburgh School of Medicine, Pittsburgh, PA 15240, USA. Roodmangd@upmc.edu
Abstract:
Multiple myeloma (MM) is a plasma cell malignancy characterized by the frequent development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone pain. In the past few years several potential factors involved in this process have been identified and, with the increased knowledge of the signaling pathways involved in the regulation of normal osteoblast and osteoclast function, have provided us with a better understanding of the contributions of the marrow microenvironment to MM bone disease. These studies have identified several potential novel targets for treating MM bone disease in addition to the current standard treatment of bisphosphonates. In this article, we discuss several potential targets for treating MM bone disease as well as novel therapies that are in clinical trials for these patients.
Insights
Multiple myeloma bone disease involves osteolytic lesions and pain. New research identifies novel therapeutic targets beyond bisphosphonates for treating these bone complications.
Area of Science:
- Oncology
- Bone Biology
- Pharmacology
Background:
- Multiple myeloma (MM) frequently causes debilitating bone disease, including osteolytic lesions and pain.
- The bone marrow microenvironment significantly contributes to MM bone pathology.
- Understanding osteoblast and osteoclast regulation is key to addressing MM bone disease.
Purpose of the Study:
- To review potential novel therapeutic targets for MM bone disease.
- To discuss emerging therapies currently in clinical trials for MM bone complications.
Main Methods:
- Literature review of recent studies on MM bone disease.
- Analysis of signaling pathways regulating bone metabolism in MM.
- Examination of ongoing clinical trials for novel MM bone therapies.
Main Results:
- Several novel targets for MM bone disease have been identified.
- Emerging therapies show promise in clinical trials.
- Enhanced understanding of the marrow microenvironment's role in MM bone disease.
Conclusions:
- Novel therapeutic strategies targeting specific pathways offer new hope for MM patients with bone disease.
- Further research and clinical trials are crucial for developing effective treatments for MM bone complications.
Related Concept Videos
02:17The Tumor Microenvironment
02:17The Tumor Microenvironment
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...